Cargando…

Cancer stem cells and their niche in cancer progression and therapy

High recurrence and metastasis rates and poor prognoses are the major challenges of current cancer therapy. Mounting evidence suggests that cancer stem cells (CSCs) play an important role in cancer development, chemoradiotherapy resistance, recurrence, and metastasis. Therefore, targeted CSC therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiuping, Guo, Zongliang, Li, Guoyin, Zhang, Yunxia, Liu, Xiaomeng, Li, Bing, Wang, Jinping, Li, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693166/
https://www.ncbi.nlm.nih.gov/pubmed/38041196
http://dx.doi.org/10.1186/s12935-023-03130-2
_version_ 1785153101106249728
author Liu, Qiuping
Guo, Zongliang
Li, Guoyin
Zhang, Yunxia
Liu, Xiaomeng
Li, Bing
Wang, Jinping
Li, Xiaoyan
author_facet Liu, Qiuping
Guo, Zongliang
Li, Guoyin
Zhang, Yunxia
Liu, Xiaomeng
Li, Bing
Wang, Jinping
Li, Xiaoyan
author_sort Liu, Qiuping
collection PubMed
description High recurrence and metastasis rates and poor prognoses are the major challenges of current cancer therapy. Mounting evidence suggests that cancer stem cells (CSCs) play an important role in cancer development, chemoradiotherapy resistance, recurrence, and metastasis. Therefore, targeted CSC therapy has become a new strategy for solving the problems of cancer metastasis and recurrence. Since the properties of CSCs are regulated by the specific tumour microenvironment, the so-called CSC niche, which targets crosstalk between CSCs and their niches, is vital in our pursuit of new therapeutic opportunities to prevent cancer from recurring. In this review, we aim to highlight the factors within the CSC niche that have important roles in regulating CSC properties, including the extracellular matrix (ECM), stromal cells (e.g., associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), and mesenchymal stem cells (MSCs)), and physiological changes (e.g., inflammation, hypoxia, and angiogenesis). We also discuss recent progress regarding therapies targeting CSCs and their niche to elucidate developments of more effective therapeutic strategies to eliminate cancer.
format Online
Article
Text
id pubmed-10693166
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106931662023-12-03 Cancer stem cells and their niche in cancer progression and therapy Liu, Qiuping Guo, Zongliang Li, Guoyin Zhang, Yunxia Liu, Xiaomeng Li, Bing Wang, Jinping Li, Xiaoyan Cancer Cell Int Review High recurrence and metastasis rates and poor prognoses are the major challenges of current cancer therapy. Mounting evidence suggests that cancer stem cells (CSCs) play an important role in cancer development, chemoradiotherapy resistance, recurrence, and metastasis. Therefore, targeted CSC therapy has become a new strategy for solving the problems of cancer metastasis and recurrence. Since the properties of CSCs are regulated by the specific tumour microenvironment, the so-called CSC niche, which targets crosstalk between CSCs and their niches, is vital in our pursuit of new therapeutic opportunities to prevent cancer from recurring. In this review, we aim to highlight the factors within the CSC niche that have important roles in regulating CSC properties, including the extracellular matrix (ECM), stromal cells (e.g., associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), and mesenchymal stem cells (MSCs)), and physiological changes (e.g., inflammation, hypoxia, and angiogenesis). We also discuss recent progress regarding therapies targeting CSCs and their niche to elucidate developments of more effective therapeutic strategies to eliminate cancer. BioMed Central 2023-12-01 /pmc/articles/PMC10693166/ /pubmed/38041196 http://dx.doi.org/10.1186/s12935-023-03130-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Liu, Qiuping
Guo, Zongliang
Li, Guoyin
Zhang, Yunxia
Liu, Xiaomeng
Li, Bing
Wang, Jinping
Li, Xiaoyan
Cancer stem cells and their niche in cancer progression and therapy
title Cancer stem cells and their niche in cancer progression and therapy
title_full Cancer stem cells and their niche in cancer progression and therapy
title_fullStr Cancer stem cells and their niche in cancer progression and therapy
title_full_unstemmed Cancer stem cells and their niche in cancer progression and therapy
title_short Cancer stem cells and their niche in cancer progression and therapy
title_sort cancer stem cells and their niche in cancer progression and therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693166/
https://www.ncbi.nlm.nih.gov/pubmed/38041196
http://dx.doi.org/10.1186/s12935-023-03130-2
work_keys_str_mv AT liuqiuping cancerstemcellsandtheirnicheincancerprogressionandtherapy
AT guozongliang cancerstemcellsandtheirnicheincancerprogressionandtherapy
AT liguoyin cancerstemcellsandtheirnicheincancerprogressionandtherapy
AT zhangyunxia cancerstemcellsandtheirnicheincancerprogressionandtherapy
AT liuxiaomeng cancerstemcellsandtheirnicheincancerprogressionandtherapy
AT libing cancerstemcellsandtheirnicheincancerprogressionandtherapy
AT wangjinping cancerstemcellsandtheirnicheincancerprogressionandtherapy
AT lixiaoyan cancerstemcellsandtheirnicheincancerprogressionandtherapy